JP5705836B2 - Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター - Google Patents
Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター Download PDFInfo
- Publication number
- JP5705836B2 JP5705836B2 JP2012512393A JP2012512393A JP5705836B2 JP 5705836 B2 JP5705836 B2 JP 5705836B2 JP 2012512393 A JP2012512393 A JP 2012512393A JP 2012512393 A JP2012512393 A JP 2012512393A JP 5705836 B2 JP5705836 B2 JP 5705836B2
- Authority
- JP
- Japan
- Prior art keywords
- her2
- gene
- gastric cancer
- patient
- neu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Description
(a)前記患者から試料を得て、
(b)
(b1)前記試料中のHER2タンパク質発現レベル、及び
(b2)前記試料中のHER2遺伝子の遺伝子増幅状態、
を評価する
工程を含み、
HER2タンパク質の不確かな発現レベル及びHER2遺伝子の高い遺伝子増幅状態は、反応する患者の指標であるか、又はHER2/neu (ErbB2)シグナル伝達経路の前記モジュレーターに対する前記患者の感受性の指標である方法である。
(a)前記患者から試料を得て、
(b)
前記試料中のHER2遺伝子の遺伝子増幅状態、
を評価する
工程を含み、
HER2タンパク質の不確かな発現レベル、及びHER2遺伝子の高い遺伝子増幅状態は反応する患者の指標であるか、又はHER2/neu (ErbB2)シグナル伝達経路の前記モジュレーターに対する前記患者の感受性の指標である方法である。
(a)胃癌を患うか又は患いやすい患者から試料を得て、
(b)
(b1)第一工程にてHER2タンパク質の発現レベル、及び
(b2)第一工程で評価したHER2タンパク質の発現レベルが不確かである場合、第二工程において前記試料中のHER2遺伝子の遺伝子増幅状態、
を評価する
工程を含み、
HER2タンパク質の不確かな発現レベル、及びHER2遺伝子の高い遺伝子増幅状態は反応する患者の指標であるか、又はHER2/neu (ErbB2)シグナル伝達経路の前記モジュレーターに対する前記患者の感受性の指標である方法である。
研究のデザイン
ToGA試験は、HER2陽性進行胃癌(GC)において、シスプラチン+フルオロピリミジン単独に対して、シスプラチン+フルオロピリミジン(カペシタビンまたは5−フルオロウラシル)と併用したトラスツズマブの安全性と有効性を調査するために設計された、無作為化、非盲検で、多施設における、第III相臨床試験である。
組み入れ基準:
−根治治療に適さない手術不能な、局所的に進行した、又は再発性の、及び/又は転移性の病変を持つ胃又は胃食道接合部(GEJ)における組織学的に確認された腺癌
−画像法技術(コンピュータ断層撮影又は磁気共鳴イメージング)を用いて評価された、固形がんの治療効果判定のためのガイドライン(RECIST)に従って測定可能な疾患、又は測定できない評価可能疾患−中央研究所により評価されたHER2陽性腫瘍(原発腫瘍または転移)。IHCとFISHの両方は、中央研究所内の全ての患者の試料(切除又は生検の何れか)において行われた。
−一般的な組み入れ基準:−男性又は女性、18才−署名付きインフォームドコンセント
主要エンドポイントは全生存期間であり、二次エンドポイントは無増悪生存期間、全奏効率と反応の持続時間を含む。有効性評価の更なる情報については要約LBA4509.10 HER2検査を参照。
ToGA試験のHER2−スクリーニングプロセスはこれで完了する。24カ国から3807の腫瘍試料は、記載の改良されたシステムを使用して中央研究所において、HER2の状態が評価されている。これらのうち、3667のサンプルは評価が可能であり、810は22.1%の全HER2陽性評価を与え、HER2陽性として定義されている。予想外に高い数値の事例は、FISH陽性/IHC0/1+であることが判明し、これらは、治療群(図1)の間で無作為であった。乳癌のHER2検査では、ほとんどのIHC 0/1+の試料はFISH陰性であることがわかっているが、ToGA試験ではIHC 0/1+/FISH−陽性検体の頻度は、IHC2+/FISH−陽性試料(それぞれ25%対28%)とほぼ同じ高さであった。IHC3+である場合のうち、5%はFISH陰性であることがわかった。
Claims (33)
- 胃癌を患っていると疑われ、HER2/neu(ErbB2)シグナル伝達経路のモジュレーターに対するレスポンダー又は感受性のある患者として、HER2タンパク質の不確かな発現レベルを有する患者を識別するためのインビトロ法であって、該方法は、
前記患者から得られた前記試料中のHER2遺伝子の遺伝子増幅状態を評価する
工程を含み、
HER2タンパク質の不確かな発現レベル、及びHER2遺伝子の高い遺伝子増幅状態が反応する患者の指標であるか、又はHER2/neu(ErbB2)シグナル伝達経路の前記モジュレーターに対する前記患者の感受性の指標である方法。 - HER2の前記タンパク質発現レベルが免疫組織化学的(IHC)方法により決定されるか又はされた、請求項1に記載の方法。
- 生検試料において決定された、HER2の前記不確かなタンパク質発現レベルがHER2(2+)である、請求項1又は2に記載の方法。
- 切除試料において決定された、HER2の前記不確かなタンパク質発現レベルがHER2(2+)である、請求項1又は2に記載の方法。
- HER2遺伝子の前記遺伝子増幅状態がインサイツハイブリダイゼーション(ISH)法によって検出される、請求項1から4の何れか一項に記載の方法。
- HER2遺伝子の前記高増幅状態が、4を超えるHER2遺伝子の平均遺伝子コピー数であるか、又は第17染色体コピーあたり2以上のHER2の平均遺伝子コピー数である、請求項1から5の何れか一項に記載の方法。
- 請求項1から6の何れかに記載の方法により識別される患者の一群のHER2/neu(ErbB2)シグナル伝達経路のモジュレーターに対する奏功率が少なくとも20%である、請求項1から6の何れか一項に記載の方法。
- 前記試料が、胃組織切除、胃組織生検、転移病巣切除由来組織、及び循環性腫瘍細胞からなる群から選択される、請求項1から7の何れか一項に記載の方法。
- 前記免疫組織化学的方法がHerceptTestTMアッセイにより実施される、請求項2から8の何れか一項に記載の方法。
- 前記インサイツハイブリダイゼーションが蛍光インサイツハイブリダイゼーション(FISH)、発色インサイツハイブリダイゼーション(CISH)及び銀インサイツハイブリダイゼーション(SISH)からなる群から選択される、請求項5に記載の方法。
- 前記FISH検査が「Inform(登録商標)」キット、「PathvysionTM」キット又は「pharmDxTM」キットからなる群から選択される、請求項10に記載の方法。
- 前記CISH検査がSPoT−Light(登録商標) HER2 CISHTM及びZytoDot(登録商標) SPEC HER2プローブキットからなる群から選択される、請求項10に記載の方法。
- 前記SISH検査はultraViewTM SISH検出キットと組み合わせた「InformTM」 HER2 DNAプローブである、請求項10に記載の方法。
- 前記試料が抗転移、ネオアジュバント、又はアジュバント療法の前に得られる、請求項1から13の何れか一項に記載の方法。
- 請求項1から14の何れか一項に記載の方法により識別される患者における胃癌の治療のための薬学的組成物の調製のためのHER2/neu(ErbB2)シグナル伝達経路のモジュレーターの使用。
- HER2/neu(ErbB2)シグナル伝達経路の前記モジュレーターがHERの二量体化/シグナル伝達阻害剤、又はHER分断阻害剤である、請求項1から14の何れか一項に記載の方法。
- 前記HERの二量体化阻害剤がHER2の二量体化阻害剤である、請求項16に記載の方法。
- 前記HERの二量体化阻害剤がHERのヘテロ二量体化又はHERのホモ二量体化を阻害する、請求項16又は17に記載の方法。
- 前記HERの二量体化阻害剤がHER抗体である、請求項16から18の何れか一項に記載の方法。
- 前記HER抗体がEGFR、HER2及びHER3からなる群から選択されるHERレセプターに結合する、請求項19に記載の方法。
- 前記抗体がHER2に結合する、請求項20に記載の方法。
- 前記HER2抗体がHER2細胞外ドメインのドメインIIに結合する、請求項21に記載の方法。
- 前記抗体がHER2細胞外ドメインのドメインI、IIとIIIの間の接合部に結合する、請求項22に記載の方法。
- 前記HER2抗体がペルツズマブである、請求項20から23の何れか一項に記載の方法。
- 前記HER分断の阻害剤がHER2分断阻害剤である、請求項16に記載の方法。
- HER分断の前記阻害剤がHERヘテロ二量体化又はHERホモ二量体化を阻害する、請求項16又は25に記載の方法。
- HER分断の前記阻害剤がHER抗体である、請求項16、25及び26の何れか一項に記載の方法。
- 前記HER抗体がEGFR、HER2及びHER3からなる群から選択されるHERレセプターに結合する、請求項27に記載の方法。
- 前記抗体がHER2に結合する、請求項28に記載の方法。
- 前記HER2抗体がHER2細胞外ドメインのサブドメインIVに結合する、請求項29に記載の方法。
- 前記HER2抗体がハーセプチン/トラツズマブである、請求項28から30の何れか一項に記載の方法。
- 前記胃癌が浸潤性胃癌である、請求項1から14の何れか一項に記載の方法。
- 前記胃癌が腸型腺癌、混合型腺癌、及びびまん型腺癌からなる群から選択される、請求項32に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09007217 | 2009-05-29 | ||
EP09007217.4 | 2009-05-29 | ||
EP10155170.3 | 2010-03-02 | ||
EP10155170 | 2010-03-02 | ||
PCT/EP2010/057429 WO2010136569A1 (en) | 2009-05-29 | 2010-05-28 | Modulators for her2 signaling in her2 expressing patients with gastric cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2012528312A JP2012528312A (ja) | 2012-11-12 |
JP5705836B2 true JP5705836B2 (ja) | 2015-04-22 |
Family
ID=42721163
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012512393A Expired - Fee Related JP5705836B2 (ja) | 2009-05-29 | 2010-05-28 | Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター |
Country Status (7)
Country | Link |
---|---|
US (1) | US20120121586A1 (ja) |
EP (1) | EP2435071A1 (ja) |
JP (1) | JP5705836B2 (ja) |
CN (1) | CN102421448A (ja) |
CA (1) | CA2761280A1 (ja) |
SG (2) | SG176073A1 (ja) |
WO (1) | WO2010136569A1 (ja) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
MX2007009889A (es) * | 2005-02-23 | 2007-09-07 | Genentech Inc | Alargar el tiempo hasta la progresion de la enfermedad o la supervivencia de los pacientes de cancer. |
EP2899541A1 (en) | 2007-03-02 | 2015-07-29 | Genentech, Inc. | Predicting response to a HER dimerisation inhbitor based on low HER3 expression |
TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至her2結構域ii之抗體及其酸性變異體的組合物 |
BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
ES2721639T3 (es) | 2010-10-06 | 2019-08-02 | Inst Catalana Recerca Estudis Avancats | Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama |
RS58944B1 (sr) | 2011-10-14 | 2019-08-30 | Hoffmann La Roche | Pertuzumab, trastuzumab, docetaksel i karboplatin za lečenje raka dojke u ranoj fazi |
CN105121471A (zh) | 2013-04-16 | 2015-12-02 | 豪夫迈·罗氏有限公司 | 帕妥珠单抗变体及其评估 |
GB2514591A (en) * | 2013-05-30 | 2014-12-03 | Mologen Ag | Predictive biomarker for cancer therapy |
JP2015071566A (ja) * | 2013-10-03 | 2015-04-16 | 住友ベークライト株式会社 | Fgf4遺伝子増幅腫瘍の医薬組成物 |
GB201317622D0 (en) * | 2013-10-04 | 2013-11-20 | Star Biotechnology Ltd F | Cancer biomarkers and uses thereof |
CN105980576B (zh) * | 2013-10-09 | 2021-07-16 | 生物医学研究机构基金会 | 用于源自乳腺癌的骨转移癌的预后和治疗的方法 |
KR102417312B1 (ko) | 2014-01-31 | 2022-07-05 | 다이이찌 산쿄 가부시키가이샤 | 항-her2 항체-약물 접합체 |
MX2016014007A (es) | 2014-04-25 | 2017-01-11 | Genentech Inc | Metodos para el tratamiento de cancer de mama temprano con trastuzumab-emtansina(mcc-dm1) y pertuzumab. |
DK3152577T3 (en) * | 2014-06-06 | 2018-10-01 | Ventana Med Syst Inc | SIGNIFICANCE OF INTRATUMORAL HER2 HETEROGENITY IN BREAST CANCER AND APPLICATIONS HEFAR |
WO2016196373A2 (en) | 2015-05-30 | 2016-12-08 | Genentech, Inc. | Methods of treating her2-positive metastatic breast cancer |
WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
AU2017271385B2 (en) | 2016-05-25 | 2023-10-05 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-MAF status |
MX2019008350A (es) | 2017-01-17 | 2019-11-11 | Genentech Inc | Formulaciones de anticuerpos de her2 subcutáneas. |
CN116531511A (zh) | 2017-03-02 | 2023-08-04 | 豪夫迈·罗氏有限公司 | Her2阳性乳腺癌的辅助治疗 |
AU2018372762A1 (en) | 2017-11-22 | 2020-05-21 | Inbiomotion S.L. | Therapeutic treatment of breast cancer based on c-maf status |
CN107868814A (zh) * | 2017-12-19 | 2018-04-03 | 威海威仕泰医疗科技有限公司 | 一种用于检测HER2基因的Dig标记探针的制备方法 |
CN112684173A (zh) * | 2020-12-09 | 2021-04-20 | 复旦大学附属中山医院 | 一种her2的检测方法及其应用 |
CN116042840A (zh) * | 2023-04-03 | 2023-05-02 | 天津云检医学检验所有限公司 | 混合型胃腺癌患者精准分型和辅助治疗的设备及制备 |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4935341A (en) | 1986-06-04 | 1990-06-19 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US7838216B1 (en) | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
DE68924979T2 (de) | 1988-04-18 | 1996-10-24 | Oncogene Science Inc | Nachweis der expression von neu genen und produkten. |
WO1990014357A1 (en) | 1989-05-19 | 1990-11-29 | Genentech, Inc. | Her2 extracellular domain |
US5705157A (en) | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US6884418B1 (en) | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
DE69033842T2 (de) | 1989-08-04 | 2002-06-20 | Schering Ag | Äusserliche domäne von c-erbb-2:gp75 |
WO1991005264A1 (en) | 1989-09-29 | 1991-04-18 | Oncogenetics Partners | Detection and quantification of neu related proteins in the biological fluids of humans |
US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
AU662311B2 (en) | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
CA2096417C (en) | 1991-08-22 | 2000-10-10 | Sarah S. Bacus | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
WO1993006217A1 (en) | 1991-09-19 | 1993-04-01 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES |
US5288477A (en) | 1991-09-27 | 1994-02-22 | Becton, Dickinson And Company | Method for prognosticating response to cancer therapy |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993012220A1 (en) | 1991-12-12 | 1993-06-24 | Berlex Laboratories, Inc. | RECOMBINANT AND CHIMERIC ANTIBODIES TO c-erbB-2 |
EP1997894B1 (en) | 1992-02-06 | 2011-03-30 | Novartis Vaccines and Diagnostics, Inc. | Biosynthetic binding protein for cancer marker |
AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
JPH08504172A (ja) | 1992-06-30 | 1996-05-07 | オンコロジクス,インコーポレイティド | 抗−erbB−2モノクロナール抗体の組み合わせ物及び使用方法 |
WO1994009022A1 (en) | 1992-10-09 | 1994-04-28 | Oncor, Inc. | Methods for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue |
CA2103323A1 (en) | 1992-11-24 | 1994-05-25 | Gregory D. Plowman | Her4 human receptor tyrosine kinase |
ES2141128T3 (es) | 1993-03-24 | 2000-03-16 | Berlex Biosciences | Combinacion de agentes anti-hormonales y moleculas de fijacion. |
AU6527894A (en) | 1993-03-30 | 1994-10-24 | Trustees Of The University Of Pennsylvania, The | Prevention of tumors with monoclonal antibodies against (neu) |
US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
US5846749A (en) | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
ATE170082T1 (de) | 1994-11-10 | 1998-09-15 | Univ Eberhard Karls | Verfahren zur wachstumshemmung von leukämischen zellen durch her-2-protein-zeilen |
EP0794792A1 (en) | 1994-12-02 | 1997-09-17 | Chiron Corporation | Method of promoting an immune response with a bispecific antibody |
US5783404A (en) | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
US5925519A (en) | 1996-06-03 | 1999-07-20 | The Regents Of The University Of California | Genetic alterations associated with prostate cancer |
US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
AU4982097A (en) | 1996-10-18 | 1998-05-15 | Board Of Regents, The University Of Texas System | Anti-erbb2 antibodies |
WO1998018489A1 (en) | 1996-10-30 | 1998-05-07 | The Uab Research Foundation | Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies |
US6468547B1 (en) | 1996-10-30 | 2002-10-22 | Uab Research Foundation | Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain secretory antibodies |
SI1900751T1 (sl) | 1996-11-27 | 2010-03-31 | Genentech Inc | Afinitetno čiščenje polipeptida na proteinskemA matriksu |
AU737910B2 (en) | 1997-01-31 | 2001-09-06 | Regents Of The University Of California, The | Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response |
US20020076695A1 (en) | 1997-04-04 | 2002-06-20 | Jeffrey S. Ross | Methods for treating prostate cancer |
US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
US6358682B1 (en) | 1998-01-26 | 2002-03-19 | Ventana Medical Systems, Inc. | Method and kit for the prognostication of breast cancer |
US20020192211A1 (en) | 1998-03-17 | 2002-12-19 | Hudziak Robert M. | Method of treating tumor cells by inhibiting growth factor receptor function |
EP1064027B1 (en) | 1998-03-27 | 2008-06-18 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
JP4469933B2 (ja) | 1998-05-06 | 2010-06-02 | ジェネンテック, インコーポレイテッド | イオン交換クロマトグラフィによるタンパク質精製 |
US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
US6403630B1 (en) | 1999-01-27 | 2002-06-11 | Cornell Research Foundation, Inc. | Treating cancers associated with overexpression of HER-2/neu |
US6333348B1 (en) | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
EP1187632B1 (en) | 1999-05-14 | 2008-12-03 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
CA2727172A1 (en) | 1999-05-26 | 2001-01-04 | Genentech, Inc. | Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
JP3485252B2 (ja) | 1999-06-16 | 2004-01-13 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 情報処理方法、情報端末支援サーバ、コラボレーション・システム、情報処理プログラムを格納する記憶媒体 |
AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
BRPI0017590B8 (pt) | 1999-06-25 | 2021-05-25 | Genentech Inc | conjugado de maitansinoide - anticorpo anti-erbb, e formulação farmacêutica |
US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
DE60033658T2 (de) | 1999-06-25 | 2007-11-22 | Genentech, Inc., South San Francisco | Behandlung von prostata-krebs mit anti-erbb2 antikörpern |
GB9917012D0 (en) | 1999-07-20 | 1999-09-22 | Pharmacia & Upjohn Spa | Combined preparations comprising antitumor agents |
NZ517372A (en) | 1999-07-29 | 2004-04-30 | Medarex Inc | Human monoclonal antibodies to HER2/neu |
KR20090126330A (ko) | 1999-08-27 | 2009-12-08 | 제넨테크, 인크. | 항-ErbB2 항체 투여 치료 방법 |
CA2383615A1 (en) | 1999-09-22 | 2001-03-29 | Corixa Corporation | Methods for diagnosis and therapy of hematological and virus-associated malignancies |
GB9925958D0 (en) | 1999-11-02 | 1999-12-29 | Bundred Nigel J | Therapeutic use |
AU2001227966A1 (en) | 2000-01-20 | 2001-07-31 | Chiron Corporation | Methods for treating tumors |
CA2397349A1 (en) | 2000-02-29 | 2001-09-07 | Ivan David Horak | Farnesyl protein transferase inhibitor combinations with an her2 antibody |
US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
US6767541B2 (en) | 2000-03-20 | 2004-07-27 | The Regents Of The University Of California | HER-2/neu overexpression abrogates growth inhibitory pathways |
US20030152572A1 (en) | 2000-04-06 | 2003-08-14 | Yoshimi Homma | Diagnostic and therapeutic agents for rheumatoid arthritis |
GB0008368D0 (en) | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
CZ20023748A3 (cs) | 2000-05-15 | 2003-04-16 | Pharmacia Italia S.P.A. | Inhibitory aromatasy a monoklonální anti-HER2 protilátky jako protitumorová činidla |
US7306801B2 (en) | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
PL400669A1 (pl) | 2000-05-19 | 2012-11-05 | Genentech, Inc. | Genowa próba wykrywania odpowiedzi na antagoniste ErbB dla poprawienia prawdopodobienstwa i skutecznosci leczenia raka |
GB0017635D0 (en) | 2000-07-18 | 2000-09-06 | Pharmacia & Upjohn Spa | Antitumor combined therapy |
TWI317285B (en) | 2000-07-28 | 2009-11-21 | Dainippon Sumitomo Pharma Co | New use and kit for remedies for cancer |
JP2004527456A (ja) | 2000-08-09 | 2004-09-09 | イムクローン システムズ インコーポレイティド | Egf受容体拮抗剤による過増殖性の疾患の治療 |
US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
US7005278B2 (en) | 2001-03-02 | 2006-02-28 | Danenberg Kathleen D | Method of determining dihydropyrimidine dehydrogenase gene expression |
US6582919B2 (en) | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
CN1488002A (zh) | 2000-12-01 | 2004-04-07 | ��˹��ŵ�� | 测定表皮生长因子受体和HER2-neu的基因表达及其水平与存活率之间相关性的方法 |
US6602670B2 (en) | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
US20020142328A1 (en) | 2000-12-01 | 2002-10-03 | Danenberg Kathleen D. | Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors |
WO2002045653A2 (en) | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
AU2002219221B2 (en) | 2001-01-09 | 2007-05-17 | Merck Patent Gmbh | Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors |
WO2002087619A1 (fr) | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Methode de prevention et de traitement du cancer |
BR0209147A (pt) | 2001-05-08 | 2004-06-08 | Merck Patent Gmbh | Terapia combinada que usa anticorpos anti-egfr e agentes anti-hormonais |
ITRM20010408A1 (it) | 2001-07-10 | 2003-01-10 | Univ Napoli Federico Ii | Mini-anticorpo umano citotossico per cellule tumorali che esprimono il recettore erbb2. |
AU2002326531A1 (en) | 2001-08-03 | 2003-02-17 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies to activated erbb family members and methods of use thereof |
US20030068318A1 (en) | 2001-09-28 | 2003-04-10 | O'brien Timothy | Treatment of uterine serous papillary cancer |
US20030096823A1 (en) | 2001-11-16 | 2003-05-22 | Beryl Asp | Method for the treatment of cardiotoxicity induced by antitumor compounds |
US20030175845A1 (en) | 2002-03-13 | 2003-09-18 | Kalbag Suresh M. | Use of sulfitolysis in high performance peptide mapping |
US20030190689A1 (en) | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
EP1492568A1 (en) | 2002-04-08 | 2005-01-05 | SmithKline Beecham Corporation | Cancer treatment method comprising administration of an erb-family inhibitor and a raf and/or ras inhibitor |
JP2005522514A (ja) | 2002-04-10 | 2005-07-28 | ジェネンテック・インコーポレーテッド | 抗her2抗体改変体 |
ITTO20020340A1 (it) | 2002-04-19 | 2003-10-20 | Biother Di Contardi Gabriella | Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. |
US20030202973A1 (en) | 2002-04-29 | 2003-10-30 | Dr. George Pieczenik | Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists |
AU2003235470A1 (en) | 2002-06-19 | 2004-01-06 | Smithkline Beecham Corporation | Predictive markers in cancer therapy |
CN101711866A (zh) | 2002-07-15 | 2010-05-26 | 健泰科生物技术公司 | 鉴定对用抗ErbB2抗体处理响应的肿瘤的方法 |
US20040013297A1 (en) | 2002-07-18 | 2004-01-22 | Roger Lo | Method for performing color gamut compression |
EP3388452A3 (en) | 2002-09-11 | 2019-02-20 | Genentech, Inc. | Protein purification |
US20040258685A1 (en) | 2002-11-21 | 2004-12-23 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-ErbB2 antibodies |
EP1570273B1 (en) | 2002-12-11 | 2018-05-30 | Ventana Medical Systems, Inc. | Method for predicting the response to her2-directed therapy |
JP2007520995A (ja) | 2003-01-08 | 2007-08-02 | ブリストル−マイヤーズ スクイブ カンパニー | 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法 |
US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
EP2949764B1 (en) | 2004-05-27 | 2018-04-11 | The Regents of The University of Colorado | Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients |
JP2009539836A (ja) | 2006-06-05 | 2009-11-19 | ジェネンテック・インコーポレーテッド | EGFまたはTGF−αのレベルの上昇が生じている癌患者の生存の延長 |
EP2088862A4 (en) * | 2006-11-28 | 2009-12-02 | Smithkline Beecham Cork Ltd | METHOD OF TREATING CANCER |
-
2010
- 2010-05-28 WO PCT/EP2010/057429 patent/WO2010136569A1/en active Application Filing
- 2010-05-28 EP EP10730108A patent/EP2435071A1/en not_active Withdrawn
- 2010-05-28 US US13/319,869 patent/US20120121586A1/en not_active Abandoned
- 2010-05-28 SG SG2011084043A patent/SG176073A1/en unknown
- 2010-05-28 SG SG10201507044PA patent/SG10201507044PA/en unknown
- 2010-05-28 CN CN2010800206998A patent/CN102421448A/zh active Pending
- 2010-05-28 CA CA2761280A patent/CA2761280A1/en not_active Abandoned
- 2010-05-28 JP JP2012512393A patent/JP5705836B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN102421448A (zh) | 2012-04-18 |
SG10201507044PA (en) | 2015-10-29 |
WO2010136569A1 (en) | 2010-12-02 |
US20120121586A1 (en) | 2012-05-17 |
SG176073A1 (en) | 2011-12-29 |
CA2761280A1 (en) | 2010-12-02 |
JP2012528312A (ja) | 2012-11-12 |
EP2435071A1 (en) | 2012-04-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5705836B2 (ja) | Her2を発現する胃癌患者のher2シグナル伝達のためのモジュレーター | |
JP7181854B2 (ja) | Pd-l1阻害剤併用療法を必要とする患者の同定 | |
Arienti et al. | Epidermal growth factor receptor family and its role in gastric cancer | |
US7829297B2 (en) | Treatment of cancers expressing p95 ErbB2 | |
Nahta et al. | Herceptin: mechanisms of action and resistance | |
Baselga | Herceptin® alone or in combination with chemotherapy in the treatment of HER2-positive metastatic breast cancer: pivotal trials | |
JP2020023495A (ja) | Erbbアンタゴニスト癌治療に対する有効な応答の可能性を向上させるための遺伝子検出アッセイ | |
Park et al. | Comprehensive analysis of HER2 expression and gene amplification in gastric cancers using immunohistochemistry and in situ hybridization: which scoring system should we use? | |
Fornaro et al. | Anti-HER agents in gastric cancer: from bench to bedside | |
US9376715B2 (en) | Methods for detecting mutations in the catalytic subunit of the phosphoinositol-3 kinase (PIK3CA) gene | |
US20060212956A1 (en) | Animal model of ligand activated HER2 expressing tumors | |
US20160289336A1 (en) | Cancer biomarkers and uses thereof | |
US20090226455A1 (en) | Combination therapy with c-met and her antagonists | |
Grillo et al. | The reliability of endoscopic biopsies in assessing HER2 status in gastric and gastroesophageal junction cancer: a study comparing biopsies with surgical samples | |
CN110536969A (zh) | 跨膜或近膜域中的erbb2/her2突变 | |
WO2010052225A1 (en) | Modulators for her2 signaling in normal her2 expressing settings | |
Gill et al. | HER-2 involvement in osteosarcoma | |
Te Velde et al. | HER-family gene amplification and expression in resected pancreatic cancer | |
Chong | Radioimmunohistochemical quantitation of EGFR and HER2 expression in preinvasive compared to invasive breast cancer and the relationship of HER2 expression in primary invasive breast cancer to outcome | |
AU2017202820A1 (en) | Combination therapy with c-met and HER antagonists | |
Lara-Guerra | EGFR in Early Non-Small Cell Lung Cancer: Tyrosine Kinase Inhibition in a Neoadjuvant Trial |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130521 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130522 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130820 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140603 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140903 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140910 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141002 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141009 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141031 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150203 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150225 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5705836 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |